Mengmeng Yang, Mingkun Zhang*, Sandra Verploegen#, Patrick Engelberts#, Yuxi Zhang*, Lei Zheng, Keyi Zhu, Annie X. An, Cunxiang Ju*, Jing Zhao*, Xiang Gao*, Henry Q.X. Li, and Davy X. Ouyang
*Nanjing Biomedical Research Institute, Nanjing University, Nanjing, China;
#Genmab B.V., Yalelaan 60, 3584 CM Utrecht, The Netherlands
Preclinical development and evaluation of T cell-redirecting antibodies is often blocked by a lack of appropriate in vivo models. These bispecific antibodies physically link tumour and T cells, usually binding to tumour associated antigens and CD3ε. There’s a lack of cross reactivity between human and mouse CD3ε, therefore standard in vivo immunocompetent murine models cannot be used.
CD3ε humanized models have been previously developed; however, these were not suitable for immunotherapy and antibody assessment due to the blockade of T lymphocyte and natural killer cell development.
This poster details the development of a new preclinical human CD3ε BAC transgenic mouse model which is phenotypically normal, and the validation of this model for T cell-redirecting antibody assessment.
Your privacy is important to us.
We'll never share your information.
© 2024 Crown Bioscience. All Rights Reserved.
© 2024 Crown Bioscience. All Rights Reserved. Privacy Policy
2021-10-27
2021-10-27
landing_page
PDX/Databases